Advisors Asset Management Inc. Purchases 1,046 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Advisors Asset Management Inc. increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,195 shares of the company’s stock after acquiring an additional 1,046 shares during the period. Advisors Asset Management Inc.’s holdings in Medpace were worth $2,390,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of MEDP. R Squared Ltd bought a new stake in shares of Medpace in the fourth quarter worth $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the fourth quarter valued at about $31,000. Stone House Investment Management LLC bought a new stake in Medpace during the third quarter valued at about $33,000. Jones Financial Companies Lllp grew its holdings in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the period. Finally, Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.4 %

Shares of Medpace stock opened at $324.23 on Friday. The stock’s 50-day simple moving average is $337.72 and its 200-day simple moving average is $339.89. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.